You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(688180.SH):XPO1抑制劑JS110獲得藥物臨牀試驗申請受理通知書
格隆匯 02-17 17:08

格隆匯 2 月 17日丨君實生物(688180.SH)公佈,近日,公司微境生物醫藥科技(上海)有限公司(“微境生物”)共同投資的蘇州君境生物醫藥科技有限公司收到國家藥品監督管理局(“國家藥監局”)核准簽發的《受理通知書》,XPO1抑制劑WJ01024(項目代號“JS110”)的臨牀試驗申請獲得受理。

JS110是核輸出蛋白XPO1的小分子抑制劑,臨牀擬用於治療晚期腫瘤病。臨牀前研究結果表明,JS110特異性阻斷XPO1蛋白功能抑制包括p53多種抑癌蛋白出核,加強抑癌蛋白功能JS110體外抑制多種腫瘤細胞生長,誘發腫瘤細胞死亡。在腫瘤動物模型中,JS110單藥或者聯用抑制多種血液和實體腫瘤生長由於其獨特的作用機制,JS110的開發有望給晚期腫瘤病人帶來全新的治療手段。

公司擁有JS110在全球範圍內的獨家生產權、委託生產權及銷售權。具體內詳見公司披露的公吿,公吿編號:2020-016

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account